Patients with low vision (visual acuity 20/400 or worse) were excluded from the large Phase
III ranibizumab clinical trials. It is not known if treatment with ranibizumab results in
improved visual function in such patients.Since ranibizumab has been shown to be the most
effective therapy for exudative macular degeneration we propose to treat all patients in this
study with monthly ranibizumab intravitreal injections.
Patients will be assigned to one of two groups by the flip of a coin. Group #1 for "heads"
and Group #2 for "tails".
Group #1 patients will be treated for 3 monthly injections of 0.5 mg of ranibizumab and then
as needed therapy.
Group #2 will be treated with 6 monthly injections of 0.5 mg of ranibizumab and then as
needed therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Steven R. Sanislo
Collaborators:
California Pacific Medical Center Genentech, Inc. Pacific Eye Associates